Cancer is one of the leading causes of death globally, and antibody-drug conjugates (ADCs) have moved from theory to reality, facilitating in the application of a biological “magic bullet” for treatment. Although ADCs present a superior alternative to traditional therapies, by combining targeted drug delivery and cytotoxicity into a single agent, the promising characteristics of these drugs are not without their own challenges and limitations.
The current ADC landscape features 654 drugs, with only 13 ADCs approved to date, of which successes have been observed with hurdles where initial approvals did not signify the end of their development journey. With well over half of the ADC landscape in preclinical development, there is growing interest for the next upcoming candidate, though it remains to be seen, as relatively few candidates reach pivotal trials.
*This webinar is English webinar
● Watch the on-demand Webinar⋙ Expert Series｜ADCs-Magic Bullets Becomes Reality | Citeline
（外部サイトが開きます）
